Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.74 is 59% above its 5-year average of -1.80, near the high end of its 5-year range (-3.47–0.39).
68.18% below its 12-month average of -0.44.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.17.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 28 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:40:59.813Z. Historical observations retain their original dates. Historical series through 2026-05-07.
EARNINGS PER SHARE (EPS)
-0.74
EARNINGS PER SHARE (EPS) AVG TTM
-0.44
EARNINGS PER SHARE (EPS) AVG 3Y
-1.32
EARNINGS PER SHARE (EPS) AVG 5Y
-1.80
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-68.18%
CURRENT VS 3Y AVG
+43.94%
CURRENT VS 5Y AVG
+58.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Black Diamond Therapeutics, Inc.
Market Cap
$108.30M
Earnings Per Share (EPS)
-0.74
TTM Avg
-0.44
3Y Avg
-1.32
5Y Avg
-1.80
Market Cap
$108.42M
Earnings Per Share (EPS)
-1.87
TTM Avg
-4.43
3Y Avg
-5.52
5Y Avg
-12.34
Market Cap
$108.02M
Earnings Per Share (EPS)
-4.80
TTM Avg
-8.13
3Y Avg
-18.81
5Y Avg
-23.77
Market Cap
$107.75M
Earnings Per Share (EPS)
-6.48
TTM Avg
-4.79
3Y Avg
-7.51
5Y Avg
-13.98
Market Cap
$107.36M
Earnings Per Share (EPS)
-0.71
TTM Avg
-0.33
3Y Avg
-0.37
5Y Avg
-0.32
Market Cap
$109.49M
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.47
3Y Avg
-0.54
5Y Avg
-0.49
Market Cap
$110.11M
Earnings Per Share (EPS)
-1.52
TTM Avg
-3.16
3Y Avg
-3.35
5Y Avg
-6.72
Market Cap
$111.14M
Earnings Per Share (EPS)
N/A
TTM Avg
-5.70
3Y Avg
-9.83
5Y Avg
-0.70
Market Cap
$105.43M
Earnings Per Share (EPS)
-1.60
TTM Avg
-2.42
3Y Avg
-1.68
5Y Avg
-1.45
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | $108.30M | -0.74 | -0.44 | -1.32 | -1.80 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.42M | -1.87 | -4.43 | -5.52 | -12.34 |
| Immunic, Inc. (IMUX)vs › | $108.02M | -4.80 | -8.13 | -18.81 | -23.77 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.75M | -6.48 | -4.79 | -7.51 | -13.98 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.36M | -0.71 | -0.33 | -0.37 | -0.32 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | -0.21 | -0.47 | -0.54 | -0.49 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.11M | -1.52 | -3.16 | -3.35 | -6.72 |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | -5.70 | -9.83 | -0.70 |
| Definitive Healthcare Corp. (DH)vs › | $105.43M | -1.60 | -2.42 | -1.68 | -1.45 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | -0.12 | -0.17 | -0.12 | -0.12 |
Trailing EPS (TTM)
$-0.74
Forward EPS (Est.)
$-0.62
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.39 |
| 2024-12-31 | -1.27 |
| 2023-12-31 | -1.88 |
| 2022-12-31 | -2.52 |
| 2021-12-31 | -3.47 |
| 2020-12-31 | -2.04 |
| 2019-12-31 | -1.15 |
| 2018-12-31 | -0.64 |
| 2017-12-31 | -0.64 |
